GIA
CARM

GHP Investment Advisors’s Carisma Therapeutics CARM Stock Holding History

GHP Investment Advisors’s Portfolio CARM Stock Details CARM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-139
Closed -$1.69K – 926
2022
Q4 		$1.69K Hold
139
– – ﹤0.01% 844
2022
Q3 		$1K Hold
139
– – ﹤0.01% 852
2022
Q2 		$2K Hold
139
– – ﹤0.01% 842
2022
Q1 		$2K Buy
+139
New +$1.94K ﹤0.01% 879

Other funds holding CARM

TOTUOP
Trustees of The University of Pennsylvania Philaldelphia, Pennsylvania $297M AUM
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DCM
Deuterium Capital Management Clearwater, Florida $86M AUM 87.31% 1-Year Est. Return
WIM
Wittenberg Investment Management Carlisle, Massachusetts $269M AUM 28.17% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

GHP Investment Advisors's CARM Position: Q1 2023 in Review

GHP Investment Advisors sold out of Carisma Therapeutics (CARM) in Q1 2023, closing a stake of 139 shares — an estimated $1.69K sold.

GHP Investment Advisors first reported a position in CARM in Q1 2022 and held it in 4 quarters. The position peaked at $2K in Q2 2022. 37 funds tracked by Wall St. Rank hold CARM as of Q1 2023.

  • GHP Investment Advisors reported no remaining Carisma Therapeutics position as of Q1 2023 after selling out during the quarter.
  • GHP Investment Advisors sold 139 Carisma Therapeutics shares in Q1 2023, an estimated $1.69K.
  • GHP Investment Advisors first reported a position in Carisma Therapeutics in Q1 2022 and held it in 4 quarters.
  • GHP Investment Advisors's Carisma Therapeutics position peaked at $2K in Q2 2022.
  • 37 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q1 2023.

Based on GHP Investment Advisors's 13F filing for Q1 2023, filed 21 Apr 2023.